

**UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING**

PBL/T-CELL CROSSMATCHING RESULTS OF SAMPLE 2A10/2014

DESPATCHED ON 26TH SEPTEMBER 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A3, A29; B44, B60; Cw10, Cw16; DR4, DR7; DQ2, DQ7

Summary of Results					Summary of Results				
Total tested	19	20	21	21	15	15	16	16	
Positive	14	1	0	0	10	0	0	0	
Negative	5	19	21	21	5	15	16	16	
Not Tested	2	2	2	2	2	2	2	2	
% Positive	73.7%	5.0%	0.0%	0.0%	66.7%	0.0%	0.0%	0.0%	
% Negative	26.3%	95.0%	100.0%	100.0%	33.3%	100.0%	100.0%	100.0%	
<b>Consensus</b>	<b>Not Assessed</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Not Assessed</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	
HLA Antibody (Defined By CDC)	Bw6	DQ3	DR7,DQ2	A32,B44,DR7					
Lab No.	Without DTT				With DTT ( Not assessed)				Comments
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
9	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	The blood was lysed - No cells recovered
11	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
12	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
14	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
15	Positive	Positive	Negative	Negative	Positive	Negative	Negative	Negative	
19	NT	NT	NT	NT	NT	NT	NT	NT	
20	Equivocal	Equivocal	Negative	Negative			Negative	Negative	
23	Positive	Negative	Negative	Negative					
24	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
25	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
28	Weak Positive	Negative	Negative	Negative	Unsatisfactory	Unsatisfactory	Unsatisfactory	Unsatisfactory	
34	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
35	Equivocal	Negative	Negative	Negative					
38	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
39	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
41	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
42	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
45	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
48	NT	NT	NT	NT	NT	NT	NT	NT	
51	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
54	Positive	Negative	Negative	Negative					
58	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
62	Positive	Negative	Negative	Negative					
									Test not performed, poor cell viability

**UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING**

PBL/T-CELL CROSSMATCHING RESULTS OF SAMPLE 2A10/2014

DESPATCHED ON 26TH SEPTEMBER 2014

Lab No.	Without DTT				With DTT (Not assessed)				Date received	Date tested	Cells used		Immunobeaded cells used?	Cell viability %		Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength			PBL	T-cells		PBL	T-cells		pre C'	post C'	
9	4	0	0	0	4	0	0	0	17-Sep	18-Sep	Yes	Yes	90		Cedarlane	30	30	AO/PI	
11									19-Sep	20-Sep	Yes	Yes	90		Cedarlane	45	90	Fluoroquencher	
12	5%	5%	5%	5%	5%	5%	5%	5%	17-Sep	17-Sep	Yes	No	95		Cedarlane	30	90	EB/AO	
14	4	0	0	0	6	0	0	0	17-Sep	17-Sep	Yes	Yes	90		Cedarlane	60	120	EB/AO	
15	4	2			4				17-Sep	17-Sep	Yes	Yes	95		TCS Biosciences	60	60	EB/AO	
19	NT	NT	NT	NT	NT	NT	NT	NT	17-Sep	18-Sep	NT	NT	NT	NT	NT	NT	NT	NT	
20			1	1			1	1	17-Sep	18-Sep	Yes	No	90		Cedarlane	30	120	EB/AO	
23	6	1	1	1					17-Sep	17-Sep	Yes	Yes	90		Cedarlane	40	40	EB/AO	
24	90%	20%	10%	20%	90%	20%	20%	20%	17-Sep	18-Sep	Yes	Yes	90		Cedarlane	45	90	EB/AO	
25	8	1	1	1	6	1	1	1	18-Sep	18-Sep	Yes	Yes	99		Cedarlane	45	60	Fluoroquencher	
28	2-4	1	1	1					17-Sep	17-Sep	Yes	Yes	90		Cedarlane	30	45	EB/AO	
34	1	1	1	1	1	1	1	1	17-Sep	17-Sep	Yes	Yes	100		Cedarlane	30	90	EB/AO	
35		1	1	1					17-Sep	18-Sep	Yes	No	90		Cedarlane	60	120	Fluoroquencher	
38	2	1	1	1	2	1	1	1	17-Sep	17-Sep	Yes	Yes	90	90	Cedarlane	60	60	EB/AO	
39	2				2				17-Sep	17-Sep	Yes	No	99		Cedarlane	45	90	EB/AO	
41	2%	2%	2%	2%	2%	2%	2%	2%	17-Sep	17-Sep	Yes	Yes	98		Cedarlane	60	60	EB/AO	
42									17-Sep	18-Sep	Yes	No	95		TCS Biosciences	60	120	EB/AO	
45	8	1	1	1	8	1	1	1	17-Sep	17-Sep	Yes	Yes	99		Cedarlane	60	90	EB/AO	
48	NT	NT	NT	NT	NT	NT	NT	NT	18-Sep	18-Sep	Yes	No	NT	NT	NT	NT	NT	NT	
51	4-8	0	0	0	8	0	0	0	17-Sep	19-Sep	Yes	Yes	95		Cedarlane	60	60	Fluoroquencher	
54	50%	0%	0%	0%					17-Sep	18-Sep	Yes	Yes	99		Cedarlane	60	60	PI	
58	50%	5%	5%	5%	90%	5%	5%	5%	17-Sep	18-Sep	Yes	Yes	95		Cedarlane	60	90	Fluoroquencher	
62	4	1	1	1					17-Sep	17-Sep	Yes	Yes	99		Cedarlane	60	120	EB/AO	

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

EB - ethidium bromide  
AO - acridine orange  
PI - propidium iodide  
Hb - haemoglobin  
CFDA - carboxy-fluorescein diacetate

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A10/2014

DESPATCHED ON 26TH SEPTEMBER 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A3, A29; B44, B60; Cw10, Cw16; DR4, DR7; DQ2, DQ7

Summary of Results					Summary of Results				
Total tested	19	19	20	20	15	15	16	16	
Positive	13	15	1	19	11	9	0	11	
Negative	6	4	19	1	4	6	16	5	
Not Tested	1	1	1	1	1	1	1	1	
% Positive	68.4%	78.9%	5.0%	95.0%	73.3%	60.0%	0.0%	68.8%	
% Negative	31.6%	21.1%	95.0%	5.0%	26.7%	40.0%	100.0%	31.3%	
<b>Consensus</b>	<b>Not Assessed</b>	<b>Positive</b>	<b>Negative</b>	<b>Positive</b>	<b>Not Assessed</b>	<b>Not Assessed</b>	<b>Negative</b>	<b>Not Assessed</b>	
HLA Antibody (Defined By CDC)	Bw6	DQ3	DR7,DQ2	A32,B44,DR7					
Lab No.	Without DTT				With DTT (Not assessed)				Comments
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
9	Positive	Positive	Negative	Positive	Positive	Positive	Negative	Positive	The blood was lysed - No cells recovered
11	Positive	Positive	Negative	Positive	Positive	Positive	Negative	Positive	
12	Negative	Positive	Negative	Weak Positive	Negative	Negative	Negative	Weak Positive	
14	Positive	Positive	Positive	Positive	Positive	Positive	Negative	Positive	
15	Positive	Positive	Negative	Positive	Positive	Positive	Negative	Positive	
19	NT	NT	NT	NT	NT	NT	NT	NT	
20	Negative	Positive	Negative	Positive	Negative	Negative	Negative	Negative	
23	Negative	Negative	Negative	Negative					
24	Positive	Positive	Negative	Positive	Positive	Positive	Negative	Positive	
25	Positive	Negative	Negative	Positive	Positive	Negative	Negative	Negative	
28	Weak Positive	Positive	Negative	Positive	Unsatisfactory	Unsatisfactory	Unsatisfactory	Unsatisfactory	
34	Positive	Positive	Negative	Positive	Positive	Positive	Negative	Negative	
38	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Negative	
39	Positive	Positive	Negative	Positive	Positive	Positive	Negative	Positive	
41	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Negative	
42	Weak Positive	Positive	Negative	Positive	Weak Positive	Negative	Negative	Weak Positive	
45	Positive	Positive	Negative	Positive	Positive	Positive	Negative	Positive	
51	Positive	Positive	Negative	Positive	Positive	Positive	Negative	Positive	
54	Positive	Positive	Negative	Positive					
58	Equivocal	Equivocal	Negative	Positive	Equivocal	Equivocal	Negative	Positive	
62	Negative	Positive	Negative	Positive					

**UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING**

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A10/2014

DESPATCHED ON 26TH SEPTEMBER 2014

Lab No.	Without DTT				With DTT (Not assessed)				Date received	Date tested	Immunobeaded cells used	B-cell viability %	Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength						pre C'	post C'	
9	2	2	0	4	2	2	0	4	17-Sep	18-Sep	Yes	90	Cedarlane	30	30	AO/PI
11	2	2		4	2	2		4	19-Sep	20-Sep	Yes	90	Cedarlane	45	90	Fluoroquench
12	2%	50%	2%	15%	2%	2%	2%	10%	17-Sep	17-Sep	Yes	98	Cedarlane	30	60	EB/AO
14	6	6	4	6	6	6	0	6	17-Sep	17-Sep	Yes	90	Cedarlane	60	120	EB/AO
15	1	1		1	1	1		1	17-Sep	17-Sep	Yes	90	TCS Biosciences	60	60	EB/AO
19	NT	NT	NT	NT	NT	NT	NT	NT	17-Sep	18-Sep	NT	NT	NT	NT	NT	NT
20	1	3	1	4	1	1	1	1	17-Sep	18-Sep	Yes	90	Cedarlane	30	60	EB/AO
23	1	1	1	1					17-Sep	17-Sep	Yes	90	Cedarlane	40	40	EB/AO
24	50%	40%	20%	50%	40%	40%	20%	40%	17-Sep	18-Sep	Yes	80	Cedarlane	45	90	EB/AO
25	4	1	1	8	4	1	1	1	18-Sep	18-Sep	Yes	99	Cedarlane	45	60	Fluoroquench
28	2-4	6-8	1	8					17-Sep	17-Sep	Yes	80	Cedarlane	30	45	EB/AO
34	4	4	1	2	4	4	1	1	17-Sep	17-Sep	Yes	85	Cedarlane	30	90	EB/AO
38	1	1	1	4	1	1	1	1	17-Sep	17-Sep	Yes	95	Cedarlane	60	60	EB/AO
39	4	4		6	4	4		6	17-Sep	17-Sep	Yes	96	Cedarlane	45	90	EB/AO
41	2%	15-20%	2%	80-90%	2%	10-15%	2%	5-10%	17-Sep	17-Sep	Yes	98	Cedarlane	60	60	EB/AO
42	20%	40%		60%	20%			20%	17-Sep	18-Sep	Yes	95	TCS Biosciences	60	120	
45	2	4-6	1	4	4	2-4	1	4-6	17-Sep	17-Sep	Yes	95	Cedarlane	30	75	EB/AO
51	2-4	2-4	0	2-6	2-4	2	0	2	17-Sep	19-Sep	Yes	95	Cedarlane	60	60	Fluoroquench
54	80%	70%	<10%	80%					17-Sep	18-Sep	Yes	95	Cedarlane	60	60	PI
58			5%	40%			5%	40%	17-Sep	17-Sep	Yes	95	Cedarlane	60	90	Fluoroquench
62	1	4	1	4					17-Sep	17-Sep	Yes	90	Cedarlane	60	120	EB/AO

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

EB - ethidium bromide  
AO - acridine orange  
PI - propidium iodide  
Hb - haemoglobin  
CFDA - carboxy-fluorescein diacetate